AstraZeneca uses currency boost to raise guidance
This article was originally published in Scrip
Executive Summary
AstraZenecaraised its full-year earnings guidance after currency exchanges proved to be a boon for its second-quarter profits and sales. The weak US dollar helped the firm to pretax profit and sales growth of 14% and 9% respectively.